National Institute for Health and Clinical Excellence (NICE)
New collaboration between NICE and The Academic Health Science Network will help embed innovations into the healthcare system for the benefit of patients
The agreement will draw on the strengths, skills, and resources of both organisations in order to seize every opportunity to support the healthcare system in adopting evidence-based healthcare and innovations
NICE and the Academic Health Science Network (AHSN) have today (4 August) announced a two-year agreement to support the use of the best evidence-based healthcare in the NHS to improve the lives of patients.
The 15 regional AHSNs were established as the AHSN Network in 2013, with a core mission to accelerate the uptake of well-evidenced innovation in the NHS in England.
NICE and the AHSN Network share the common purpose of identifying and accelerating the uptake of well-evidenced innovations into the healthcare system and to improve quality, safety, outcomes and experience, as well as the effective use of resources. This shared purpose underpins the aim to improve healthcare in the UK, and globally, and to support the UK's reputation as a leader in healthcare innovation.
The two organisations have previously worked together to support and accelerate the rate of adoption and spread of evidence-based practice and innovation in the NHS. This formalised collaboration will focus on drawing together the expertise and resources of both organisations to deliver these improvements more effectively.
The agreement outlines priority areas of work that the collaboration will focus on, including addressing market challenges for digital innovation, shaping and generating real world evidence, and supporting innovators into the healthcare system.
Expert teams from NICE and the AHSN Network will meet regularly throughout the year to develop a programme of work to deliver these priorities.
Prof Gillian Leng, NICE chief executive, said:
“By working together more closely we can increase the speed at which innovative new medicines and technologies recommended by NICE can be cascaded through the healthcare system. Our work with the AHSN Network will also ensure we are helping to produce the vital real-world evidence needed to guide the development of NICE recommendations.
“One of the key priorities of our new 5-year strategy is to increase the uptake and use of NICE recommendations across the healthcare system to maximise the impact of our work and ensure everyone has access to the latest innovations. We can best achieve this by working strategically with our key partners such as the AHSN Network, and we’re delighted to announce this new collaboration between our organisations.”
Prof Gary Ford, chair of the AHSN Network, chief executive of Oxford AHSN and non-executive director for NICE, said:
“This agreement builds on the successes of our past collaborative working and will help us further our work to ensure patients have access to the latest evidence-based technologies, advice and guidance.
“NICE and the Network share a common goal to accelerate the rate of adoption and spread of evidence-based practice and innovation within the NHS, and by working together we can use our combined expertise and experience to improve health at pace and scale.”
Richard Stubbs, vice chair of the AHSN Network and chief executive of Yorkshire & Humber AHSN, said:
“As a Network our aim is to transform lives through innovation. The role NICE plays in evidence generation and health and care excellence makes them an ideal partner for us to collaborate and work more closely with to support the spread and adoption of innovative solutions that meet the needs of patients and the health and care system.”
Latest News from
National Institute for Health and Clinical Excellence (NICE)
Update on the NICE ME/CFS guideline roundtable discussion22/09/2021 09:10:00
The roundtable meeting to discuss the updated guideline on the diagnosis and management of ME/CFS will be held on October 18th in London. It is being convened after publication of the guideline was paused when issues were raised by some professional groups during the pre-publication period
NICE and PHE recommend all employers give mental health training for managers17/09/2021 11:10:00
All managers should be given the skills to support employees with mental health issues, NICE and PHE have said in new guidance.
NICE recommends treatment for people with juvenile idiopathic arthritis10/09/2021 11:15:00
NICE yesterday (9 September 2021) published final draft guidance which recommends tofacitinib (also known as Xeljanz and made by Pfizer) as an option for treating active polyarticular juvenile arthritis and juvenile psoriatic arthritis in people 2 years and older.
Professor Gillian Leng to retire from NICE09/09/2021 14:15:00
Professor Leng has spent more than 20 years working at NICE.
NICE draft guidance recommends apalutamide for treating prostate cancer08/09/2021 12:20:00
NICE has today (8 September 2021) published final draft guidance which now recommends apalutamide (also called Erleada and made by Janssen) plus androgen deprivation therapy for treating prostate cancer in adults
Sharing evidence with NICE is part of a broader approach to help Cochrane to identify priority reviews02/09/2021 11:15:00
Toby Lasserson, deputy editor in chief at Cochrane, writes about a new collaborative agreement with NICE, how it will work and what it means for the health service.
NICE approves ground-breaking cholesterol-lowering drug inclisiran01/09/2021 13:05:00
NICE has today (1 September 2021) issued draft final guidance recommending the novel anti-cholesterol drug inclisiran (Leqvio and made by Novartis) for people with primary hypercholesterolaemia or mixed dyslipidaemia who have already had a cardiovascular event such as a heart attack or stroke
NICE and Cochrane sign collaborative agreement to deliver ‘living’ guideline recommendations01/09/2021 12:05:00
NICE and Cochrane have today (01st September 2021) signed a collaborative agreement which will help to deliver ‘living’ recommendations across the NICE guideline portfolio.
NICE announces next steps for ME/CFS guideline31/08/2021 09:15:00
NICE recognises the importance to patients of the updated guideline on the diagnosis and management of myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome (ME/CFS) and is keen to move forwards as quickly as possible.